Document is current
Any future updates will be listed below
-
Authors
Cox, Robert M. http://orcid.org/0000-0003-0620-1674
Lieber, Carolin M.
Wolf, Josef D. http://orcid.org/0000-0003-2507-6944
Karimi, Amirhossein
Lieberman, Nicole A. P. http://orcid.org/0000-0001-9334-8150
Sticher, Zachary M. http://orcid.org/0000-0002-7022-1410
Roychoudhury, Pavitra http://orcid.org/0000-0002-4567-8232
Andrews, Meghan K. http://orcid.org/0000-0001-8491-3824
Krueger, Rebecca E. http://orcid.org/0000-0003-1962-7578
Natchus, Michael G.
Painter, George R.
Kolykhalov, Alexander A.
Greninger, Alexander L.
Plemper, Richard K. http://orcid.org/0000-0003-2034-2107
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI141222, AI171403, AI171403)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
- License Information
-
More Information
Article History
Received: 28 November 2022
Accepted: 1 August 2023
First Online: 7 August 2023
Competing interests
: G.R.P., MGN., and A.A.K. receive licensing fees and royalties based on Emory’s sublicense of the molnupiravir technology to Ridgeback Biotherapeutics, and a family member of GRP serves as the Chief Medical Officer of Ridgeback. This technology is the subject of the research described in this paper. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict-of-interest policies. R.K.P. reports contract testing from Enanta Pharmaceuticals and Atea Pharmaceuticals, and research support from Gilead Sciences, outside of the described work. R.M.C. reports consulting for Merck & Co, outside of the described work. A.L.G. reports contract testing from Abbott, Cepheid, Novavax, Pfizer, Janssen, and Hologic and research support from Gilead Sciences and Merck, outside of the described work. All other authors declare that they have no competing interests to report.
